These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37527044)

  • 21.
    Boughdad S; Latifyan S; Fenwick C; Bouchaab H; Suffiotti M; Moslehi JJ; Salem JE; Schaefer N; Nicod-Lalonde M; Costes J; Perreau M; Michielin O; Peters S; Prior JO; Obeid M
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34686542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids.
    Jindal T; Kumar A; Venkitaraman B; Dutta R; Kumar R
    Korean J Intern Med; 2010 Dec; 25(4):386-91. PubMed ID: 21179276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of
    Imperiale A; Boursier C; Sahakian N; Ouvrard E; Chevalier E; Sebag F; Addeo P; Taïeb D
    J Nucl Med; 2022 Mar; 63(3):384-388. PubMed ID: 34272321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 68 Ga-DOTATOC PET/CT Imaging of a Muscular Solitary Fibrous Tumor.
    Richard C; Cros J; Seban RD; Champion L; Hescot S
    Clin Nucl Med; 2023 May; 48(5):e228-e229. PubMed ID: 36854307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
    Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
    J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.
    Müssig K; Oksüz MO; Dudziak K; Ueberberg B; Wehrmann M; Horger M; Schulz S; Häring HU; Pfannenberg C; Bares R; Gallwitz B; Petersenn S
    Horm Metab Res; 2010 Jul; 42(8):599-606. PubMed ID: 20422506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.
    Schreiter NF; Brenner W; Nogami M; Buchert R; Huppertz A; Pape UF; Prasad V; Hamm B; Maurer MH
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):72-82. PubMed ID: 21927931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of SSTR2 Expression Assessed by
    Fonti R; Panico M; Pellegrino S; Pulcrano A; Vastarella LA; Torbati AHM; Giuliano M; Palmieri G; De Placido S; Del Vecchio S
    J Nucl Med; 2022 Oct; 63(10):1509-1514. PubMed ID: 35273092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and significance of incidental findings on 68 Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT: a systematic review of the literature.
    Bentestuen M; Gossili F; Almasi CE; Zacho HD
    Cancer Imaging; 2022 Sep; 22(1):44. PubMed ID: 36057635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
    Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
    Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from
    Thuillier P; Liberini V; Grimaldi S; Rampado O; Gallio E; Santi B; Arvat E; Piovesan A; Filippi R; Abgral R; Molinari F; Deandreis D
    J Nucl Med; 2022 Jul; 63(7):1014-1020. PubMed ID: 34740949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies.
    Lincke T; Singer J; Kluge R; Sabri O; Paschke R
    Thyroid; 2009 Apr; 19(4):381-9. PubMed ID: 19355828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma.
    Schartinger VH; Dudás J; Decristoforo C; Url C; Schnabl J; Göbel G; Virgolini IJ; Riechelmann H; Rasse M; Waitz D; Putzer D
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1365-72. PubMed ID: 23685751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
    Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H
    Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using
    Ilan E; Velikyan I; Sandström M; Sundin A; Lubberink M
    J Nucl Med; 2020 Feb; 61(2):217-221. PubMed ID: 31302632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.